Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrgastro.2010.150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease.
Gut Liver
January 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Alcohol-related liver disease (ALD) is a serious global health concern, characterized by liver inflammation and progressive fibrosis. There are no Food and Drug Administration-approved drugs, thus effective treatments are needed. Severe alcoholic hepatitis (AH) is the most severe manifestation of ALD, with a 28-day mortality rate ranging from 20% to 50%.
View Article and Find Full Text PDFRifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial.
Ann Hepatol
December 2024
Department of Internal Medicine, Bucheon Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Bucheon, South Korea.
Introduction And Objectives: The short-term mortality of severe alcoholic hepatitis (SAH) is high, but there are no effective treatments to improve short-term mortality other than corticosteroids. This study investigated the effects of adding rifaximin to standard treatment in patients with SAH.
Material And Methods: In this randomized controlled open-label trial, patients with SAH (Maddrey's discriminant function≥32) were randomized to the rifaximin or control group.
Prolonged use of pentoxifylline increases the life expectancy of patients with compensated cirrhosis: A 20‑year retrospective study.
Biomed Rep
December 2024
Division of Immunology, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, Jalisco 44340, Mexico.
Liver cirrhosis is a pathology of varied etiology with a high prevalence and mortality, resulting in >1 million mortalities per year. Patients with liver cirrhosis typically have a survival time of 12 years following diagnosis. The treatment for this disease is directed at the complications of cirrhosis; however, to the best of our knowledge, the long-term management of patients with cirrhosis has been scarcely studied.
View Article and Find Full Text PDFPipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
J Clin Transl Hepatol
September 2024
Department of Gastroenterology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- There is a growing global concern over metabolic dysfunction-associated steatotic liver disease (MASLD), yet no licensed medications exist for its treatment.
- Recent research has illuminated the complex nature of MASLD, paving the way for the development of new drugs and repurposing existing ones.
- Treatment strategies focus on four key pathways: antidiabetic medications, managing hepatic lipid accumulation, addressing oxidative stress/inflammation, and targeting gut health, with combination therapies seen as a promising approach for improved effectiveness and reduced side effects.
Impact of fecal microbiota transplantation in severe alcoholic hepatitis: A systematic review and meta-analysis.
JGH Open
August 2024
Department of Pharmacy and Therapeutics, Faculty of Pharmacy Kuwait University Kuwait City Kuwait.
Article Synopsis
- Severe alcoholic hepatitis (SAH) is a critical condition with limited treatment options, and fecal microbiota transplantation (FMT) is being explored as a potential therapy.
- A meta-analysis of six studies involving 371 SAH patients found that those receiving FMT had significantly better survival rates at 1 and 3 months compared to those receiving standard care.
- However, the survival benefits of FMT diminished after 6 months, suggesting a need for further research into its long-term effectiveness and ways to maintain these benefits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!